Evidence map›Paper›PMID 34037090›Full record

ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2021

The protective effect of lycopene against oxidative kidney damage associated with combined use of isoniazid and rifampicin in rats.

F Bedir, H Kocaturk, O Turangezli, E Sener, S Akyuz, F B Ozgeris, B Dabanlioglu, H Suleyman, D Altuner, B Suleyman

Open access · goldAbstract read
In one paragraph

Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Lycopene: A Potent Antioxidant with Multiple Health Benefits.Journal of nutrition and metabolism · 2024
    Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

F BedirDepartment of Urology, Health Sciences University, Erzurum Regional Training and Research Hospital, Erzurum, Turkey.ORCID http://orcid.org/0000-0003-0506-0777
H KocaturkDepartment of Urology, Health Sciences University, Erzurum Regional Training and Research Hospital, Erzurum, Turkey.ORCID http://orcid.org/0000-0002-7254-7692
O TurangezliDepartment of Urology, Health Sciences University, Erzurum Regional Training and Research Hospital, Erzurum, Turkey.ORCID http://orcid.org/0000-0002-1792-9620
E SenerDepartment of Pathology, Faculty of Medicine, Ataturk University, Erzurum, Turkey.ORCID http://orcid.org/0000-0002-0632-3527
S AkyuzDepartment of Microbiology, Mengucek Gazi Training and Research Hospital, Erzincan, Turkey.ORCID http://orcid.org/0000-0003-1999-7827
F B OzgerisDepartment of Nutrition and Dietetics, Faculty of Health Sciences, Ataturk University, Erzurum, Turkey.ORCID http://orcid.org/0000-0002-4568-5782
B DabanliogluDepartment of Microbiology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey.ORCID http://orcid.org/0000-0002-6953-7266
H SuleymanDepartment of Pharmacology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey.ORCID http://orcid.org/0000-0002-9239-4099
D AltunerDepartment of Pharmacology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey.ORCID http://orcid.org/0000-0002-5756-3459
B SuleymanDepartment of Pharmacology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey.ORCID http://orcid.org/0000-0001-5795-3177
Erzincan Binali Yıldırım University · TRErzurum Regional Training and Research Hospital · TRAtatürk University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is known that the combined use of antibiotics, such as isoniazid and rifampicin, in the treatment of tuberculosis causes oxidative kidney damage. The aim of this study was to biochemically and histopathologically investigate the effect of lycopene on oxidative kidney damage due to the administration of isoniazid and rifampicin in albino Wistar male rats. Lycopene at a dose of 5 mg/kg was orally administered to lycopene+isoniazid+rifampicin (LIR) rats, and normal sunflower oil (0.5 mL) was orally administered to isoniazid+rifampicin (IR) and healthy control (HG) rats as vehicle by gavage. One hour after the administration of lycopene and vehicle, 50 mg/kg isoniazid and rifampicin were given orally to the LIR and IR groups. This procedure was performed once a day for 28 days. Rats were sacrificed by a high dose of anesthesia at the end of this period, and oxidant-antioxidant parameters were measured in the removed kidney tissues. Creatinine and blood urea nitrogen (BUN) levels were measured in blood samples, and kidney tissues were also evaluated histopathologically. The combined administration of isoniazid and rifampicin changed the oxidant-antioxidant balance in favor of oxidants, and it increased blood urea nitrogen and creatinine levels, which are indicators of kidney function. Co-administration of isoniazid and rifampicin also caused oxidative kidney damage. Lycopene biochemically and histopathologically decreased oxidative kidney damage induced by isoniazid and rifampicin administration. These results suggested that lycopene may be beneficial in the treatment of nephrotoxicity due to isoniazid and rifampicin administration.

Indexed as

IsoniazidRifampinAnimalsAntioxidantsCarotenoidsKidneyLycopeneMaleOxidative StressRatsAntioxidantsCarotenoidsIsoniazidLycopeneRifampin

Identifiers

PMID34037090
PMCPMC8148980
OpenAlexW3163477746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.